Cargando…

Single application of high-intensity focused ultrasound as primary therapy of localized prostate cancer: Treatment-related predictors of biochemical outcomes

OBJECTIVE: Recent reports on high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer suggest that preoperative risk groups of tumor recurrence are strong predictors of oncological outcomes. The purpose of this study is to determine the prognostic significance of treatment-rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Pfeiffer, Dietrich, Berger, Juergen, Gross, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Second Military Medical University 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730698/
https://www.ncbi.nlm.nih.gov/pubmed/29264119
http://dx.doi.org/10.1016/j.ajur.2014.08.009
_version_ 1783286398085758976
author Pfeiffer, Dietrich
Berger, Juergen
Gross, Andreas
author_facet Pfeiffer, Dietrich
Berger, Juergen
Gross, Andreas
author_sort Pfeiffer, Dietrich
collection PubMed
description OBJECTIVE: Recent reports on high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer suggest that preoperative risk groups of tumor recurrence are strong predictors of oncological outcomes. The purpose of this study is to determine the prognostic significance of treatment-related factors in relation to patient characteristics for biochemical outcomes after HIFU. METHODS: This retrospective single-center study included patients treated from December 2002 to December 2010 for localized prostate cancer with two generations of Ablatherm(®) HIFU devices (A1 and A2). All the patients underwent single HIFU treatment session under the concept of whole-gland therapy. Prostate surgery was performed before HIFU to downsize enlarged glands. Androgen deprivation therapy (ADT) was discontinued before HIFU. Biochemical failure (BCF) was defined as prostate specific antigen (PSA) nadir + 1.2 ng/mL (Stuttgart definition). Predictors of BCF were determined using Cox regression models. As covariates, patient-related factors (age, tumor characteristics, ADT) were compared with treatment-related factors (prostate volume, HIFU device generation, conduct of therapy, prostate edema, patient movement, anesthetic modalities). RESULTS: Three hundred and twenty-three (98.8%) out of 327 consecutive patients were evaluable for BCF. Median (interquartile range) follow-up was 51.2 (36.6–80.4) months. The overall BCF-rate was 23.8%. In multivariate analyses, higher initial PSA-values (Hazard ratio [HR]: 1.03; p < 0.001) and higher D'Amico risk stages (HR: 3.45; p < 0.001) were patient-related predictors of BCF. Regarding treatment-related factors, the A2 HIFU device was associated with a decreased risk of BCF (HR: 0.51; p = 0.007), while prostate edema had an adverse effect (HR: 1.8; p = 0.027). Short follow-up and retrospective study design are the primary limitations. CONCLUSION: Success in a single HIFU session depends not merely on tumor characteristics, but also on treatment-related factors. Ablation is more efficacious with the technically advanced A2 HIFU device. Heat-induced prostate edema might adversely affect the outcome.
format Online
Article
Text
id pubmed-5730698
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Second Military Medical University
record_format MEDLINE/PubMed
spelling pubmed-57306982017-12-20 Single application of high-intensity focused ultrasound as primary therapy of localized prostate cancer: Treatment-related predictors of biochemical outcomes Pfeiffer, Dietrich Berger, Juergen Gross, Andreas Asian J Urol Article OBJECTIVE: Recent reports on high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer suggest that preoperative risk groups of tumor recurrence are strong predictors of oncological outcomes. The purpose of this study is to determine the prognostic significance of treatment-related factors in relation to patient characteristics for biochemical outcomes after HIFU. METHODS: This retrospective single-center study included patients treated from December 2002 to December 2010 for localized prostate cancer with two generations of Ablatherm(®) HIFU devices (A1 and A2). All the patients underwent single HIFU treatment session under the concept of whole-gland therapy. Prostate surgery was performed before HIFU to downsize enlarged glands. Androgen deprivation therapy (ADT) was discontinued before HIFU. Biochemical failure (BCF) was defined as prostate specific antigen (PSA) nadir + 1.2 ng/mL (Stuttgart definition). Predictors of BCF were determined using Cox regression models. As covariates, patient-related factors (age, tumor characteristics, ADT) were compared with treatment-related factors (prostate volume, HIFU device generation, conduct of therapy, prostate edema, patient movement, anesthetic modalities). RESULTS: Three hundred and twenty-three (98.8%) out of 327 consecutive patients were evaluable for BCF. Median (interquartile range) follow-up was 51.2 (36.6–80.4) months. The overall BCF-rate was 23.8%. In multivariate analyses, higher initial PSA-values (Hazard ratio [HR]: 1.03; p < 0.001) and higher D'Amico risk stages (HR: 3.45; p < 0.001) were patient-related predictors of BCF. Regarding treatment-related factors, the A2 HIFU device was associated with a decreased risk of BCF (HR: 0.51; p = 0.007), while prostate edema had an adverse effect (HR: 1.8; p = 0.027). Short follow-up and retrospective study design are the primary limitations. CONCLUSION: Success in a single HIFU session depends not merely on tumor characteristics, but also on treatment-related factors. Ablation is more efficacious with the technically advanced A2 HIFU device. Heat-induced prostate edema might adversely affect the outcome. Second Military Medical University 2015-01 2015-04-16 /pmc/articles/PMC5730698/ /pubmed/29264119 http://dx.doi.org/10.1016/j.ajur.2014.08.009 Text en © 2015 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier (Singapore) Pte Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Pfeiffer, Dietrich
Berger, Juergen
Gross, Andreas
Single application of high-intensity focused ultrasound as primary therapy of localized prostate cancer: Treatment-related predictors of biochemical outcomes
title Single application of high-intensity focused ultrasound as primary therapy of localized prostate cancer: Treatment-related predictors of biochemical outcomes
title_full Single application of high-intensity focused ultrasound as primary therapy of localized prostate cancer: Treatment-related predictors of biochemical outcomes
title_fullStr Single application of high-intensity focused ultrasound as primary therapy of localized prostate cancer: Treatment-related predictors of biochemical outcomes
title_full_unstemmed Single application of high-intensity focused ultrasound as primary therapy of localized prostate cancer: Treatment-related predictors of biochemical outcomes
title_short Single application of high-intensity focused ultrasound as primary therapy of localized prostate cancer: Treatment-related predictors of biochemical outcomes
title_sort single application of high-intensity focused ultrasound as primary therapy of localized prostate cancer: treatment-related predictors of biochemical outcomes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730698/
https://www.ncbi.nlm.nih.gov/pubmed/29264119
http://dx.doi.org/10.1016/j.ajur.2014.08.009
work_keys_str_mv AT pfeifferdietrich singleapplicationofhighintensityfocusedultrasoundasprimarytherapyoflocalizedprostatecancertreatmentrelatedpredictorsofbiochemicaloutcomes
AT bergerjuergen singleapplicationofhighintensityfocusedultrasoundasprimarytherapyoflocalizedprostatecancertreatmentrelatedpredictorsofbiochemicaloutcomes
AT grossandreas singleapplicationofhighintensityfocusedultrasoundasprimarytherapyoflocalizedprostatecancertreatmentrelatedpredictorsofbiochemicaloutcomes